Please login to the form below

Not currently logged in
Email:
Password:

David Colpman joins Forendo Pharma’s board

He becomes a non-executive director

David ColpmanForendo Pharma, a drug development company, has appointed David Colpman to its board of directors.

Colpman, who becomes the group’s non-executive director, brings with him a career of more than 25 years in pharma and biotech business development and strategy.

He said: “I see great opportunities for Forendo, and look forward to working with the experienced team in the company.”

His previous roles include head of global business development at Shire and business development and commercial positions at Glaxo Wellcome - now GlaxoSmithKline - and Novo Nordisk.

Risto Lammintausta, chief executive officer of Forendo Pharma, said: “We are delighted to welcome David with his broad experience in the industry that will be of significant benefit to Forendo.

“His insights and expertise will be very helpful as we continue to evaluate the commercial alternative of our programmes.”

29th March 2018

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides powerful, insight-driven, scientific and medical communication services to the pharmaceutical industry across the globe, with...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics